
|Videos|January 12, 2017
An Overview of the TnAcity Trial in TNBC
Author(s)Denise Yardley, MD
Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the phase II tnAcity trial in triple-negative breast cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Indefinite Myeloma Maintenance Shows No OS Benefit vs 2-Year Duration
5




























